Should I use pregabalin or gabapentin for neuropathic pain, epilepsy adjunct therapy, or generalized anxiety, considering efficacy, safety, dosing, and renal function?

Pregabalin vs Gabapentin: Clinical Recommendation

For neuropathic pain, pregabalin is the preferred first-line agent over gabapentin due to superior efficacy, faster onset of pain relief, simpler dosing, and better tolerability. 1, 2

Neuropathic Pain Management

Why Pregabalin is Superior

Pregabalin demonstrates faster and more effective pain control compared to gabapentin across multiple neuropathic pain conditions 2. A 2024 meta-analysis of 3,346 patients showed pregabalin achieved significantly better VAS scores at all time points up to 12-14 weeks (SMD -0.47,95% CI -0.74 to -0.19), resulted in more days with no/mild pain (MD 9.00 days), and led to 50% lower opioid consumption (OR 0.50) 2.

The pharmacokinetic advantages are clinically meaningful 1, 3:

• Pregabalin has linear, predictable absorption (>90% bioavailability at all doses) while gabapentin has saturable absorption that drops from 60% to 33% as doses increase from 900 to 3600 mg/day 3
• Pregabalin reaches therapeutic effect faster because the initial 150 mg/day dose is already efficacious, whereas gabapentin requires 2+ months of titration to reach adequate dosing 1
• Pregabalin dosing is straightforward: start 150 mg/day divided BID-TID, increase to 300 mg/day after 1 week 1, 4
• Gabapentin dosing is complex: requires slow titration starting at 100-300 mg, increasing every 1-7 days up to 3600 mg/day over 3-8 weeks 1

Specific Indications

For diabetic peripheral neuropathy:

• Pregabalin is "established as effective" (Level A recommendation) 5
• Gabapentin is "probably effective" (Level B recommendation) 5
• Start pregabalin at 50 mg TID (150 mg/day), increase to 300 mg/day within 1 week; maximum 300 mg/day 4

For postherpetic neuralgia:

• Both are first-line agents 1
• Pregabalin: 75-150 mg BID (150-300 mg/day), can increase to 600 mg/day if needed 4
• Pregabalin provides analgesia more quickly due to faster titration 1

For spinal cord injury neuropathic pain:

• Pregabalin is FDA-approved; start 75 mg BID, increase to 150 mg BID within 1 week, maximum 300 mg BID 4

Safety Profile

Pregabalin has fewer adverse events 2:

• Lower incidence of nausea/vomiting compared to gabapentin 2
• Both cause dose-dependent dizziness and sedation 1
• Critical caveat: Pregabalin is Schedule V controlled substance in the US due to abuse potential 1
• Rare but serious: myoclonus can occur even without renal dysfunction 6

Cost-Effectiveness

Pregabalin is significantly more cost-effective despite potentially higher drug acquisition costs 7:

• 75% reduction in cost per VAS point improvement 7
• 72% decrease in cost per McGill pain point 7
• Three-month treatment cost: INR 1,286 for pregabalin vs INR 3,420 for gabapentin 7
• Lower costs driven by faster efficacy, simpler dosing, and reduced need for dose escalation

Epilepsy (Adjunctive Therapy for Partial-Onset Seizures)

Both are effective adjunctive agents, but pregabalin may have greater magnitude of seizure reduction 3. However, gabapentin has longer clinical track record in epilepsy.

Dosing for epilepsy:

• Pregabalin: Adults start 150 mg/day, maximum 600 mg/day divided BID-TID 4
• Gabapentin: Requires individual titration up to 3600 mg/day
• Important: The efficacy of adding pregabalin to gabapentin has not been studied; avoid combining 4

Generalized Anxiety Disorder

Pregabalin is effective for GAD and may be considered when first-line SSRIs/SNRIs fail 8. A 2025 meta-analysis showed pregabalin superior to placebo and comparable to benzodiazepines/SSRIs/SNRIs with better tolerability and lower discontinuation rates (OR 0.80) 8. Gabapentin is not FDA-approved for anxiety disorders.

Renal Impairment: Critical Dosing Adjustments

Both drugs require dose reduction in renal impairment as they are renally eliminated 1, 4:

For pregabalin (adjust based on creatinine clearance) 4:

• CrCl ≥60 mL/min: No adjustment needed
• CrCl 30-60 mL/min: Reduce dose by 50%
• CrCl 15-30 mL/min: Reduce dose by 75%
• CrCl <15 mL/min: Reduce dose by 85-90%
• Hemodialysis: Give supplemental dose after each 4-hour session 4

For gabapentin: Similar renal-based adjustments required 1

Common pitfall: Failure to adjust doses in elderly patients with age-related renal decline leads to accumulation and increased adverse effects, particularly myoclonus 6.

Clinical Algorithm for Selection

Choose Pregabalin when:

• Starting new neuropathic pain treatment (any etiology)
• Rapid pain control is needed
• Patient compliance concerns exist (simpler dosing)
• Cost-effectiveness is priority (when considering total treatment costs)
• Diabetic peripheral neuropathy (strongest evidence)

Choose Gabapentin when:

• Pregabalin is unavailable or unaffordable (drug acquisition cost)
• Concern about controlled substance prescribing
• Patient already stable on gabapentin with good response
• Very elderly or frail patients where slower titration preferred

Avoid combining pregabalin and gabapentin - no evidence of benefit and increases adverse effect risk 4.